TY - JOUR
T1 - How important is coronary artery disease when considering lung transplant candidates?
AU - Koprivanac, Marijan
AU - Budev, Marie M.
AU - Yun, James J.
AU - Kelava, Marta
AU - Pettersson, Gösta B.
AU - McCurry, Kenneth R.
AU - Johnston, Douglas R.
AU - Mangi, Abeel A.
AU - Houghtaling, Penny L.
AU - Blackstone, Eugene H.
AU - Murthy, Sudish C.
N1 - Funding Information:
This study was partly supported by the Gus P. Karos Registry Fund, the Peter and Elizabeth C. Tower and Family Endowed Chair in Cardiothoracic Research (held by G.B.P.), James and Sharon Kennedy, the Slosburg Family Charitable Trust, Stephen and Saundra Spencer, Martin Nielsen, the Kenneth Gee and Paula Shaw, PhD, Chair in Heart Research (held by E.H.B.), and the Daniel and Karen Lee Endowed Chair in Thoracic Surgery (held by S.C.M.). These individuals and organizations played no role in the collection of data or analysis and interpretation of the data and had no right to approve or disapprove publication of the finished manuscript.
Publisher Copyright:
© 2016 International Society for Heart and Lung Transplantation
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Background Coronary artery disease (CAD) remains a relative contraindication for lung transplantation, but should it be if amenable to effective palliation? Methods From January 2005 to July 2010, 356 adults undergoing primary lung transplantation had no significant (<50%) coronary arterial stenosis and 70 had significant (≥50%) CAD requiring prior or concomitant revascularization. Propensity matching on 38 pre-transplant patient characteristics identified 61 well-matched pairs (87% of possible matches) and 295 no-CAD unmatched patients to compare post-operative morbidity, graft function, and time-related pulmonary function and survival. Results Compared with no-CAD patients, those with CAD intervention were older, more likely to be male, had more comorbidities, and were more likely to have idiopathic pulmonary fibrosis. Among propensity-matched patients, 5 died in-hospital in the CAD intervention group and 6 in the no-CAD group (p = 0.7). Intensive care unit stay (5 vs 7 days), post-operative stay (14 vs 15 days), tracheostomy requirement (12 vs 11 patients), primary graft dysfunction scores (p >0.8), and early longitudinal post-transplant pulmonary function (p = 0.2) were similar, as was time-related mortality (20% vs 22% and 51% vs 52% at 1 and 4 years, respectively; p = 0.6). Unmatched no-CAD patients had fewer comorbidities and lower mortality than matched patients (15% and 39% at 1 and 4 years, respectively; p = 0.01). Conclusions CAD is an important risk factor in lung transplant candidates, but its influence can be minimized in experienced centers by effective palliation. Surprisingly, however, CAD is a marker for an unfavorable patient phenotype with worse than typical post-transplant survival, irrespective of whether CAD is present.
AB - Background Coronary artery disease (CAD) remains a relative contraindication for lung transplantation, but should it be if amenable to effective palliation? Methods From January 2005 to July 2010, 356 adults undergoing primary lung transplantation had no significant (<50%) coronary arterial stenosis and 70 had significant (≥50%) CAD requiring prior or concomitant revascularization. Propensity matching on 38 pre-transplant patient characteristics identified 61 well-matched pairs (87% of possible matches) and 295 no-CAD unmatched patients to compare post-operative morbidity, graft function, and time-related pulmonary function and survival. Results Compared with no-CAD patients, those with CAD intervention were older, more likely to be male, had more comorbidities, and were more likely to have idiopathic pulmonary fibrosis. Among propensity-matched patients, 5 died in-hospital in the CAD intervention group and 6 in the no-CAD group (p = 0.7). Intensive care unit stay (5 vs 7 days), post-operative stay (14 vs 15 days), tracheostomy requirement (12 vs 11 patients), primary graft dysfunction scores (p >0.8), and early longitudinal post-transplant pulmonary function (p = 0.2) were similar, as was time-related mortality (20% vs 22% and 51% vs 52% at 1 and 4 years, respectively; p = 0.6). Unmatched no-CAD patients had fewer comorbidities and lower mortality than matched patients (15% and 39% at 1 and 4 years, respectively; p = 0.01). Conclusions CAD is an important risk factor in lung transplant candidates, but its influence can be minimized in experienced centers by effective palliation. Surprisingly, however, CAD is a marker for an unfavorable patient phenotype with worse than typical post-transplant survival, irrespective of whether CAD is present.
KW - cardiac revascularization
KW - coronary artery disease
KW - graft function
KW - lung transplantation
KW - morbidity
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=84971668023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84971668023&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2016.03.011
DO - 10.1016/j.healun.2016.03.011
M3 - Article
C2 - 27266805
AN - SCOPUS:84971668023
SN - 1053-2498
VL - 35
SP - 1453
EP - 1461
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 12
ER -